Uberti-Foppa C - Search Results

1

Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.

Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H; European HIV Cohorts. Kirk O, et al. Ann Intern Med. 2002 Aug 20;137(4):239-50. doi: 10.7326/0003-4819-137-4-200208200-00008. Ann Intern Med. 2002. PMID: 12186514

2

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.

Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L; EuroSIDA Study. Mocroft A, et al. Clin Infect Dis. 2020 May 6;70(10):2131-2140. doi: 10.1093/cid/ciz601. Clin Infect Dis. 2020. PMID: 31504296 Free article.

3

The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.

Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van Bremen K, Beniowski M, Mikhalik J, Cavassini M, Maltez F, Duvivier C, Uberti Foppa C, Knysz B, Bakowska E, Kuzovatova E, Domingo P, Zagalo A, Viard JP, Degen O, Milinkovic A, Benfield T, Peters L; EuroSIDA study group. Mocroft A, et al. HIV Med. 2022 Jul;23(6):585-598. doi: 10.1111/hiv.13210. Epub 2021 Dec 9. HIV Med. 2022. PMID: 34889022

4

Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.

Mussini C, Manzardo C, Johnson M, Monforte Ad, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C; Late Presenter Investigators. Mussini C, et al. AIDS. 2008 Nov 30;22(18):2461-9. doi: 10.1097/QAD.0b013e328314b5f1. AIDS. 2008. PMID: 19005269

5

Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.

Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A. Uberti-Foppa C, et al. J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):146-52. doi: 10.1097/00126334-200306010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12794546 Clinical Trial.

6

Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or Chronicity.

Morsica G, Galli L, Bossolasco S, Bagaglio S, Vercesi R, Salpietro S, Hasson H, Messina E, Castagna A, Uberti-Foppa C. Morsica G, et al. J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):175-180. doi: 10.1097/QAI.0000000000002106. J Acquir Immune Defic Syndr. 2019. PMID: 31192822

7

Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.

Pastori C, Weiser B, Barassi C, Uberti-Foppa C, Ghezzi S, Longhi R, Calori G, Burger H, Kemal K, Poli G, Lazzarin A, Lopalco L. Pastori C, et al. Blood. 2006 Jun 15;107(12):4825-33. doi: 10.1182/blood-2005-06-2463. Epub 2006 Mar 7. Blood. 2006. PMID: 16522810 Free PMC article.

8

Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection.

Lillo FB, Lodini S, Ferrari D, Stayton C, Taccagni G, Galli L, Lazzarin A, Uberti-Foppa C. Lillo FB, et al. Clin Infect Dis. 2005 Feb 1;40(3):451-7. doi: 10.1086/427032. Epub 2005 Jan 7. Clin Infect Dis. 2005. PMID: 15668870

9

Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.

Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A. Seminari E, et al. J Antimicrob Chemother. 2007 Oct;60(4):831-6. doi: 10.1093/jac/dkm282. Epub 2007 Aug 7. J Antimicrob Chemother. 2007. PMID: 17684056

10

Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.

Morsica G, Bianchi G, Bagaglio S, Conte C, Salpietro S, Porrino L, Uberti-Foppa C. Morsica G, et al. New Microbiol. 2011 Jul;34(3):317-21. Epub 2011 Jul 30. New Microbiol. 2011. PMID: 21811753 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

134 results

Search Page